Eton Pharmaceuticals Names Judith Matthews as CFO Effective June 1, 2026
Eton Pharmaceuticals will appoint Judith M. Matthews as CFO on June 1, 2026, with outgoing CFO James Gruber remaining through May and then consulting for six months. Matthews brings over 25 years of financial leadership in fast-growing pharmaceutical firms, including 11 years as Iterum Therapeutics’ CFO.
1. CFO Succession Plan
Eton Pharmaceuticals has announced that Judith M. Matthews will assume the role of Chief Financial Officer on June 1, 2026. James Gruber will remain as CFO through May 31 and then provide financial advisory support under a six-month consulting agreement.
2. New CFO Background
Ms. Matthews brings over 25 years of finance leadership in pharmaceutical and biotech firms, including 11 years as CFO at Iterum Therapeutics and a tenure as Vice President of Finance at Durata Therapeutics. She holds a B.A. in Accounting from the University of Illinois and a Master of Management in Finance and Marketing from Kellogg School of Management.
3. Outgoing CFO Transition
James Gruber has led Eton’s finance department for four years, overseeing rapid revenue growth and multiple product integrations. His upcoming consulting role is designed to ensure continuity and support strategic financial initiatives during the leadership transition.
4. Strategic Outlook
Eton currently markets ten rare-disease products and has four late-stage development candidates. The new CFO will be responsible for financial planning and capital allocation to drive the company’s next growth phase.